Colchicine treatment for heart attack recovery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effects of colchicine on coronary reperfusion and infarct size in patients with acute coronary syndrome (ACS). Participants will receive a loading dose of 1.5 mg of colchicine followed by 0.5 mg daily for six weeks. The study aims to address the inadequacies of current treatments that often fail to reduce myocardial damage despite successful revascularization. By targeting inflammation associated with atheroma plaque complications, this trial seeks to improve outcomes for ACS patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥18 years.
2. Adults hospitalized at the Clinical Hospital of the Catholic University for an ACS condition, defined as:

   \- Presence of chest pain, associated with enzymatic elevation (increase of ultrasensitive troponin above normal value (99th percentile)) with or without electrocardiographic changes.
3. Patients undergoing coronary angiography with the intention of angioplasty in the next few days (during the index hospitalization).
4. Ability and willingness to provide written informed consent.

Exclusion Criteria:

1. ST-segment elevation myocardial infarction (undergoing emergency angioplasty therefore not allowing time for the administration and effect of colchicine).
2. Severe left main stenosis.
3. Advanced heart failure, left ventricular ejection fraction \<35%.
4. Related to colchicine use: known intolerance, previous use for another condition (e.g., gout), severe liver disease (e.g., severe liver disease).
5. Severe liver disease (transaminase elevation 3 times above normal), blood dyscrasia (leukocyte or platelet count lower than normal), glomerular filtration rate (MDRD), use of CYP3A4 or calcineurin inhibitors, active autoimmune disease or the use of chronic anti-inflammatory therapy, concomitant infection, pregnancy or concomitant infection, pregnancy or lactation.
6. Any other disease that limits life expectancy to \<1 year.
7. Medical history of a disorder that could, in the opinion of the treating physician, place the participant at significant risk if they were to participate in the trial.

Where it's running

• Hospital Clínico Pontificia Universidad Catolica de Chile
  Santiago, Santiago Metropolitan, Chile Recruiting

Study contacts

• Principal investigator: Gonzalo Martínez, MD — Pontificia Universidad Catolica de Chile
• Study coordinator: Gonzalo Martínez, MD
• Email: gmartinezr@med.puc.cl
• Phone: 56 223543218

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Common femoral vein-to-artery diameter ratio to detect elevated LVEDP

  Researchers test whether the ratio of the common femoral vein to artery diameters, measured by ultrasound, can flag elevated LV end-diastolic pressure in patients having coronary angiography.

  Recruiting Burapha University · Chon Buri · NCT07866859

• Intrahospital flu vaccine for adults with high cardiovascular risk when admitted for ACS or heart failure

  This study tests whether offering a flu vaccine at the bedside during a hospital stay, along with counseling, increases vaccination rates for adults with acute coronary syndrome or heart failure who are at high cardiovascular risk.

  Recruiting at 2 sites University Hospital of Cologne · Cologne and 1 other locations · NCT07721649

• Digital lifestyle platform after rehabilitation to support self-management

  A digital, patient-facing platform is being tested to see if people who recently finished inpatient rehabilitation will use it and benefit from personalized lifestyle guidance at home.

  Recruiting at 2 sites Insel Gruppe AG, University Hospital Bern · Bern, Canton of Bern and 1 other locations · NCT07597031

• AI-driven Medipixel fractional flow reserve to guide PCI

  This test checks whether an AI-based, angiography-derived Medipixel FFR method can guide PCI as safely and effectively as standard invasive pressure-wire FFR in adults with coronary artery disease.

  Recruiting at 23 sites Samsung Medical Center · Seoul, Select State and 22 other locations · NCT07329699

• Freesolve resorbable magnesium scaffold vs. Xience stent for up to two new heart artery lesions

  This trial tests whether the Freesolve resorbable magnesium scaffold works as well as the Xience drug-eluting stent for treating up to two new coronary artery lesions in adults.

  Recruiting at 3 sites Teleflex · Washington D.C., District of Columbia and 2 other locations · NCT07258290

• AI-assisted interpretation of chest pain CT in the emergency department

  A pragmatic randomized trial tests whether an AI tool (Angiomics) helps emergency physicians interpret coronary CT angiography in adults with acute chest pain.

  Recruiting Yonsei University · Seoul · NCT07235657

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.